發(fā)布時間：2018-09-14 21:11

【摘要】：目前抗人表皮生長因子受體2(human epidermal growth factor receptor-2,HER-2)陽性乳腺癌臨床研究關(guān)注不同機(jī)制下靶向藥物的聯(lián)合、靶向藥物與內(nèi)分泌治療聯(lián)合、雙靶向藥物與化療藥物聯(lián)合,目的是為未來抗HER-2臨床治療指明方向。本文著重介紹國內(nèi)外在研的Ⅱ~Ⅲ期臨床試驗,同時介紹有較好應(yīng)用潛能的靶向藥物,主要包括新型小分子靶向藥物、單克隆抗體靶向藥物、單克隆抗體偶聯(lián)物、雙靶點藥物聯(lián)合治療、靶向藥物聯(lián)合內(nèi)分泌治療、靶向聯(lián)合化療、曲妥珠單抗皮下注射制劑、HER-2腫瘤疫苗等。
[Abstract]:At present, clinical studies of anti-human epidermal growth factor receptor 2 (human epidermal growth factor receptor-2,HER-2) positive breast cancer focus on the combination of targeted drugs under different mechanisms, targeted drugs combined with endocrine therapy, dual-targeted drugs and chemotherapeutic drugs. The aim is to point out the direction of future anti-HER-2 clinical therapy. In this paper, the phase 鈪，

本文編號：2243871